GlassScriptPhysician profile
Ben H Quinney
NPI 1245239342
$2,168.06
in general payments reported to CMS, 2019-2025
33 companies · $23.17 in 2025
The $23.17 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,225 · 2020: $452 · 2021: $118 · 2022: $163 · 2023: $165 · 2024: $21.09 · 2025: $23.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $209.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $445.67 | 2019-2023 | |
| Janssen Biotech, INC. | $351.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $173.81 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $152.56 | 2023 | Imbruvica, Epkinly |
| E.R. Squibb & Sons, L.L.C. | $133.00 | 2019 | |
| Amgen INC. | $117.07 | 2019-2021 | |
| Coherus Oncology, INC. | $84.64 | 2020-2021 | |
| Daiichi Sankyo INC. | $80.09 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $66.18 | 2019-2020 | |
| Celgene Corporation | $52.67 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.71 | 2019-2020 | |
| Genzyme Corporation | $45.19 | 2019 | |
| Pfizer INC. | $44.83 | 2019 | |
| Genentech USA, INC. | $32.37 | 2019 | |
| Glaxosmithkline, LLC. | $28.25 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.11 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $25.30 | 2019-2020 | |
| Sobi, INC | $23.17 | 2025 | |
| Tesaro, INC. | $22.75 | 2019 | |
| Eisai INC. | $22.42 | 2019 | |
| Abbvie INC. | $21.09 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.64 | 2019 | |
| Exelixis INC. | $20.03 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.00 | 2020 | |
| Dova Pharmaceuticals | $15.81 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $15.16 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.17 | 2019 | |
| Incyte Corporation | $12.71 | 2021 | |
| Astellas Pharma US INC | $12.52 | 2019 | |
| Emmaus Medical, INC. | $12.08 | 2019 | |
| Mallinckrodt Hospital Products INC. | $11.78 | 2020 | |
| Seagen INC. | $11.62 | 2021 | |
| Gilead Sciences, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Quinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.